Immunology - CurrentMed (Page 3)

Immunology

Research Progress on Inflammation and Immune Dysregulation in PTSD

PMCID: PMC12171638 PMID: 40525295 DOI: 10.1002/brb3.70633 Journal: Brain and behavior Publication Date: 2025-6-17 Authors: Yang L, Lu J, Zhao Z, Zhang Z, Yang W, et al. Key Points * PTSD is characterized by significant immune system dysregulation with consistent pro-inflammatory cytokine elevations * Multiple studies demonstrated increased inflammatory markers

Immunology

Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia

PMCID: PMC12173385 PMID: 40526635 DOI: 10.1371/journal.pone.0324443 Journal: PloS one Publication Date: 2025-6-17 Authors: Vrana C, Zhang M, Rochette M, Alozie M, Oviedo H, et al. Key Points * NAMPT inhibition represents a promising targeted therapeutic approach for T-ALL * FK866 increased median survival by 39.5 days in

Immunology

CAR‐NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor

PMCID: PMC12171998 PMID: 40525700 DOI: 10.1002/iid3.70210 Journal: Immunity, inflammation and disease Publication Date: 2025-6-17 Authors: Cao Y, Wang L, Wang L Key Points * CAR-NK cells provide a safer, more adaptable immunotherapy alternative to CAR-T cells * Potential for "off-the-shelf" manufacturing reduces personalization complexity and treatment time

Immunology

Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis

PMCID: PMC12174348 PMID: 40527893 DOI: 10.1038/s41467-025-60628-1 Journal: Nature communications Publication Date: 2025-6-17 Authors: Kanno A, Kito T, Maeda M, Yamaki S, Amano Y, et al. Key Points * First monovalent antibody designed to specifically block pathogenic NMDAR autoantibodies without receptor dysfunction * Demonstrated 74% reversal of NMDAR internalization at 2.

Immunology

Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy

PMCID: PMC12175482 PMID: 40530896 DOI: 10.1002/cam4.70994 Journal: Cancer medicine Publication Date: 2025-6-18 Authors: Wang F, Chen W, Jia Y, He T, Wu S, et al. Key Points * Intestinal microbiota significantly modulates immunotherapy response in colorectal cancer * Specific bacterial strains can enhance CD8+ T cell infiltration and cytotoxicity

Immunology

Narrowing Down Key Players in Autoimmunity via Single‐Cell Multiomics

PMCID: PMC12177686 PMID: 40534591 DOI: 10.1002/eji.202451233 Journal: European journal of immunology Publication Date: 2025-6-19 Authors: Gjurgjaj A, Conde CD Key Points * Single-cell multiomics provides unprecedented insights into the molecular mechanisms underlying autoimmune diseases * Emerging computational integration and deep-learning tools show promise for disease stratification and drug prioritization

Immunology

Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers

PMCID: PMC12179044 PMID: 40536705 DOI: 10.1007/s00262-025-04091-3 Journal: Cancer immunology, immunotherapy : CII Publication Date: 2025-6-19 Authors: Gustafson AM, Dinerman AJ, Hitscherich KJ, Parkhurst MR, Halas H, et al. Key Points * Lung metastases demonstrated superior TIL growth (95%) compared to other resection sites * 51% of TIL harvests showed high neoantigen

Immunology

Lymphocyte immunophenotype in dogs with immune-mediated hematologic disease

PMCID: PMC12173396 PMID: 40526723 DOI: 10.1371/journal.pone.0326341 Journal: PloS one Publication Date: 2025-6-17 Authors: Blois SL, Cuq BY, Bienzle D Key Points * Dogs with IMHD demonstrated significantly lower proportions of CD4+ and CD8+ lymphocytes compared to healthy controls (p < 0.0001) * T regulatory cells were reduced

Immunology

TIGIT blockade improves anti-Mycobacterium tuberculosis immunity

PMCID: PMC12173411 PMID: 40526725 DOI: 10.1371/journal.ppat.1013228 Journal: PLoS pathogens Publication Date: 2025-6-17 Authors: Zhou J, Yang Q, Xu H, Chen H, Jiang N, et al. Key Points * TIGIT expression on CD8+ T cells is significantly elevated in active TB patients and correlates with disease severity * TIGIT

Immunology

Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?

PMCID: PMC12178997 PMID: 40536609 DOI: 10.1007/s12032-025-02822-1 Journal: Medical oncology (Northwood, London, England) Publication Date: 2025-6-19 Authors: Zamani MR, Šácha P Key Points * Non-antibody immune checkpoint inhibitors represent a promising frontier in cancer immunotherapy, offering more targeted and potentially less toxic treatment approaches * Multiple novel ICI candidates are currently